Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. - Wikidata - awgldk - TriplyDB

Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate.

Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate.

http://www.wikidata.org/entity/Q34004782

about

Splicing therapy for neuromuscular disease Progress toward therapy with antisense-mediated splicing modulation Molecular Biology and Infection of Hepatitis E Virus Re-directing an alkylating agent to mitochondria alters drug target and cell death mechanism Silencing disease genes in the laboratory and the clinic Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy.Delivery is key: lessons learnt from developing splice-switching antisense therapies Evaluation of Tris[2-(acryloyloxy)ethyl]isocyanurate cross-linked polyethylenimine as antisense morpholino oligomer delivery vehicle in cell culture and dystrophic mdx mice Antiviral and neuroprotective role of octaguanidinium dendrimer-conjugated morpholino oligomers in Japanese encephalitis.Effective dystrophin restoration by a novel muscle-homing peptide-morpholino conjugate in dystrophin-deficient mdx mice.Exon skipping restores dystrophin expression, but fails to prevent disease progression in later stage dystrophic dko mice Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity.Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus.Bi-specific splice-switching PMO oligonucleotides conjugated via a single peptide active in a mouse model of Duchenne muscular dystrophy.Splice-correction strategies for treatment of X-linked agammaglobulinemia.Arginine-rich cell-penetrating peptide dramatically enhances AMO-mediated ATM aberrant splicing correction and enables delivery to brain and cerebellum.Inhibition of hepatitis E virus replication by peptide-conjugated morpholino oligomers.The use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the mdx mouse.Cationic polyelectrolyte-mediated delivery of antisense morpholino oligonucleotides for exon-skipping in vitro and in mdx mice.Development and Application of an Ultrasensitive Hybridization-Based ELISA Method for the Determination of Peptide-Conjugated Phosphorodiamidate Morpholino Oligonucleotides.Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs.Progress in gene therapy of dystrophic heart disease.Delivery of steric block morpholino oligomers by (R-X-R)4 peptides: structure-activity studies.Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophy.Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice.Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides.Development of a general methodology for labelling peptide-morpholino oligonucleotide conjugates using alkyne-azide click chemistry.Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.Cell-targeting and cell-penetrating peptides for delivery of therapeutic and imaging agents.The role of carrier size in the pharmacodynamics of antisense and siRNA oligonucleotides.Bioanalysis of siRNA and oligonucleotide therapeutics in biological fluids and tissues.Potential therapeutic applications of antisense morpholino oligonucleotides in modulation of splicing in primary immunodeficiency diseases Targeting RNA to treat neuromuscular disease.Therapeutic potential of cell-penetrating peptides.Canonical and non-canonical barriers facing antimiR cancer therapeutics Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases.Development of therapeutic splice-switching oligonucleotides.Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.Cell-Penetrating Peptides for Antiviral Drug Development.Inhibition of Pseudomonas aeruginosa by Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers.

P2860

Q27009581-412D746C-136C-49E7-9BD5-592AB6F2F048 Q27489807-DE1C9309-6EF2-4FD0-991C-1B17072EA952 Q28066101-F65B0857-4D66-4380-B370-5E3EA2E97C9B Q28486104-5D89175B-6FED-4FD3-A210-7F70E81156A3 Q29039090-DCFE779F-80C5-46A6-B425-7CD95CF5690F Q33594805-F356E203-4320-4B83-BE05-100D7CB41C66 Q33625875-DFFB85C9-EA73-4210-BCDF-D116AE817965 Q33637696-A46C78E8-C937-4FA3-ACE6-6C91649F6768 Q33761035-AC945B01-7D33-49FD-A76C-9A501247489C Q33870687-46B8EF80-C120-4197-961F-DF04DD9E944B Q34204198-C31088F5-DAAF-401A-B1F4-9224A7B0231E Q34463222-FDA04E5F-6B79-46B1-85F8-766CF02A6C2E Q34787775-53C931F6-934F-4823-BEC6-3227918573CC Q34883011-33703E51-E3DC-42B6-84F8-E254BB9A9DEF Q35033817-FED3F38A-BBA9-4F53-AF74-CC3EB4C83814 Q35119681-263D5419-F404-4408-AEEE-FDD88F6B84FB Q35853760-61B3F66D-BB7F-4AA1-ACA8-0C9F8368FE78 Q35881677-EC5B9907-3820-4340-B872-3994B4AFF2F7 Q36036988-C54924E0-3E10-412A-AFEB-116E9C0AC5AE Q36078437-9FB78562-E3C5-4407-82F7-7BCED61659A9 Q36297940-3820102A-65B6-4C98-B6B8-8A5A84C3D5C2 Q36773242-05C806EB-5B84-41DF-84CF-79AC094D161C Q36972120-A26D9269-CF98-429B-BC0F-188497ECC74E Q37021623-954B6204-ECF8-4D7F-9EEA-D08356C8C412 Q37165327-4A2AB5CC-2581-47F0-998A-50286572D2D7 Q37193000-7B73EB71-8ABF-4D64-A4FA-C5D94CCF9169 Q37276200-232C4738-9149-4F27-958F-37082B5C59A4 Q37419563-A52B88C4-36B8-466F-BBBD-FDB060129960 Q37668316-270DCCC8-0DB2-4139-AB98-D7334ABC9879 Q37724167-A69C5C5E-5E1C-4D22-8F64-DD14F5B9499A Q37810190-05CBE69A-FBE4-450B-8EDE-A55A44D587B0 Q37819299-B6D04798-6968-4FBE-9A71-7CB39EB5DCA7 Q37909000-2C592102-BDC5-42DF-88D2-AC9AFA5843C3 Q38104407-F363D0FB-14C5-4A75-9023-4E848C1BB987 Q38112723-2E3C10F3-10BB-4755-BCEA-C81FD33D63E9 Q38186137-044109C1-81DE-4429-8FC6-649861B1FADC Q38211673-8849DC5B-DADA-424C-BEF2-BB60E9331FA8 Q38734734-4CCEE205-9F5B-44D8-AC02-FF473230AD6A Q38974187-AD9012DD-3DAB-45CC-919A-D3AB8A89EA01 Q38991210-32448864-E27E-4645-9889-9C912C56D68D

P2860

Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate.

http://www.wikidata.org/entity/Q34004782

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Pharmacokinetics, biodistribut ...... morpholino oligomer conjugate.

@ast

Pharmacokinetics, biodistribut ...... morpholino oligomer conjugate.

@en

Pharmacokinetics, biodistribut ...... morpholino oligomer conjugate.

@nl

type

label

Pharmacokinetics, biodistribut ...... morpholino oligomer conjugate.

@ast

Pharmacokinetics, biodistribut ...... morpholino oligomer conjugate.

@en

Pharmacokinetics, biodistribut ...... morpholino oligomer conjugate.

@nl

prefLabel

Pharmacokinetics, biodistribut ...... morpholino oligomer conjugate.

@ast

Pharmacokinetics, biodistribut ...... morpholino oligomer conjugate.

@en

Pharmacokinetics, biodistribut ...... morpholino oligomer conjugate.

@nl

P1433

Q34004782-F8DD93F2-4408-44DC-AE89-CF00C893A07E

P1476

Q34004782-2D85FB8D-1636-42DE-AEF6-3DB8BE96D028

P2093

Q34004782-13C92CA1-99C1-41E1-ABB7-8DBB4872C4F9

Q34004782-2FE7E66F-1A4A-4AF2-BD8C-D9A46E27FF05

Q34004782-5FB6CEAC-6B54-465B-801C-56E36D16C6C3

Q34004782-6372D330-A1CC-429B-9F6F-85DB6446D0FC

Q34004782-67C12857-DE77-48AF-9EC7-578A65BAB5B6

Q34004782-7CD3E6A2-A74B-4319-9FFA-A86C623CC5B0

Q34004782-EABE2EE0-01A7-4F19-B5E1-D495FF1E83A2

P304

Q34004782-B7777073-37B0-46E1-9F8E-0E5C10935ED5

P31

Q34004782-954D7EB3-32A3-4022-BE3E-97455241A407

P356

Q34004782-A8EAD039-FB1A-4480-9CE1-0519C454A892

P433

Q34004782-E5A01DC0-89E8-48B3-BDDB-1FAABC816E7E

P478

Q34004782-6A81A31D-5E17-4488-98C7-8B202678C54C

P50

Q34004782-A0A30828-00A3-4AC9-9863-AF5725C32571

P577

Q34004782-C8E0430E-922A-4F89-9E64-D05C83533524

P698

Q34004782-7FF2F26A-3470-4654-9F0B-5B82157801F7

P356

P1433

Bioconjugate Chemistry

P1476

Pharmacokinetics, biodistribut ...... -morpholino oligomer conjugate

@en

P2093

Adams Amantana

http://www.w3.org/2001/XMLSchema#string

Derek S Youngblood

http://www.w3.org/2001/XMLSchema#string

Hong M Moulton

http://www.w3.org/2001/XMLSchema#string

Jed N Hassinger

http://www.w3.org/2001/XMLSchema#string

Melissa L Cate

http://www.w3.org/2001/XMLSchema#string

Muralimohan T Reddy

http://www.w3.org/2001/XMLSchema#string

Tom Whitehead

http://www.w3.org/2001/XMLSchema#string

P304

1325-1331

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/BC070060V

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Patrick L Iversen

P577

2007-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17583927

http://www.w3.org/2001/XMLSchema#string